PPTD.F logo

PeptiDreamOTCPK:PPTD.F Stock Report

Market Cap US$1.4b
Share Price
US$11.50
My Fair Value
US$25
54.3% undervalued intrinsic discount
1Yn/a
7D1.4%
Portfolio Value
View

PeptiDream (PPTD.F) Stock Overview

A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. More details

PPTD.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance6/6
Financial Health5/6
Dividends0/6

PPTD.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

PeptiDream Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PeptiDream
Historical stock prices
Current Share PriceJP¥11.50
52 Week HighJP¥18.00
52 Week LowJP¥10.82
Beta0.16
1 Month Change3.60%
3 Month Change-12.25%
1 Year Changen/a
3 Year Change17.95%
5 Year Change-73.34%
Change since IPO-88.32%

Recent News & Updates

Recent updates

Shareholder Returns

PPTD.FUS BiotechsUS Market
7D1.4%-1.7%0.8%
1Yn/a-13.2%13.7%

Return vs Industry: Insufficient data to determine how PPTD.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PPTD.F performed against the US Market.

Price Volatility

Is PPTD.F's price volatile compared to industry and market?
PPTD.F volatility
PPTD.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: PPTD.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PPTD.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006736Patrick Crawford Reidwww.peptidream.com

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.

PeptiDream Inc. Fundamentals Summary

How do PeptiDream's earnings and revenue compare to its market cap?
PPTD.F fundamental statistics
Market capUS$1.42b
Earnings (TTM)US$100.60m
Revenue (TTM)US$316.81m
14.1x
P/E Ratio
4.5x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PPTD.F income statement (TTM)
RevenueJP¥46.68b
Cost of RevenueJP¥12.19b
Gross ProfitJP¥34.49b
Other ExpensesJP¥19.67b
EarningsJP¥14.82b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 06, 2025

Earnings per share (EPS)114.77
Gross Margin73.89%
Net Profit Margin31.75%
Debt/Equity Ratio34.7%

How did PPTD.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 13:40
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PeptiDream Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Akinori UedaGoldman Sachs